{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:14:25Z","timestamp":1763097265063,"version":"3.45.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Secukinumab has demonstrated favorable efficacy and safety in the management of plaque psoriasis; however, its use in generalized pustular psoriasis (GPP) remains limited, particularly in children under 6 years of age, with only a few clinical reports available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>A 4-month-old infant was admitted with a 2-month history of GPP, which had worsened over the previous week with extensive erythematous rashes and pruritus. More than 70% of the body surface area was affected, with progression toward erythroderma. The Japanese Dermatological Association Severity Index score was 7, indicating moderate severity. Treatment with secukinumab 50 mg weekly, combined with daily emollients, was initiated. Complete clearance of skin lesions was achieved after four injections. One year after discontinuation of secukinumab, recurrence occurred; a single re-administration of secukinumab resulted in near-complete resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab may provide potential clinical benefits with an acceptable safety profile in infants with GPP. Further research is required to establish the optimal treatment duration, dosing intervals, and long-term safety in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1713628","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:38Z","timestamp":1763097038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment with secukinumab in a 4-month-old infant with severe generalized pustular psoriasis: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Long","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lequ","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s13555-022-00881-0","article-title":"Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment","volume":"13","author":"Rivera-D\u00edaz","year":"2023","journal-title":"Dermatol Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/PTT.S146004","article-title":"Secukinumab in the treatment of psoriasis: patient selection and perspectives","volume":"8","author":"Yang","year":"2018","journal-title":"Psoriasis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/1346-8138.15673","article-title":"Excellent response to secukinumab in an infant with severe generalized pustular psoriasis","volume":"48","author":"L\u00f3pez-S\u00e1nchez","year":"2021","journal-title":"J Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1111\/1346-8138.15228","article-title":"Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis","volume":"47","author":"Nishida","year":"2020","journal-title":"J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2340\/00015555-2467","article-title":"Secukinumab in the treatment of generalized pustular psoriasis: a case report","volume":"97","author":"Polesie","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1097\/CM9.0000000000001244","article-title":"Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases","volume":"133","author":"Sun","year":"2020","journal-title":"Chin Med J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1111\/1346-8138.15645","article-title":"Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab","volume":"48","author":"Akaji","year":"2021","journal-title":"J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: a review in moderate to severe pediatric plaque psoriasis","volume":"23","author":"Blair","year":"2021","journal-title":"Paediatr Drugs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/jcm12041662","article-title":"Interleukin-17 vs. interleukin-23 inhibitors in pustular and erythrodermic psoriasis: a retrospective, multicentre cohort study","volume":"12","author":"Avallone","year":"2023","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.2147\/JIR.S472338","article-title":"Comparative efficacy and safety of ustekinumab and secukinumab in the treatment of generalized pustular psoriasis: a 48-week retrospective cohort study with genetic background analysis","volume":"17","author":"Ruan","year":"2024","journal-title":"J Inflamm Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1377381","DOI":"10.3389\/fmed.2024.1377381","article-title":"Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature","volume":"11","author":"Wei","year":"2024","journal-title":"Front Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.intimp.2018.06.020","article-title":"Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Cui","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/PTT.S509495","article-title":"Treatment of psoriasis with II-17 inhibitors: comparison of long-term effectiveness and drug survival of secukinumab vs ixekizumab in real-world practice","volume":"15","author":"Lam","year":"2025","journal-title":"Psoriasis."},{"key":"B16","first-page":"55","article-title":"Comparison of guidelines for the use of interleukin-17 inhibitors for psoriasis in the United States, Britain, and Europe: a critical appraisal and comprehensive review","volume":"14","author":"Kearns","year":"2021","journal-title":"J Clin Aesthet Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1713628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:39Z","timestamp":1763097039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1713628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":16,"alternative-id":["10.3389\/fmed.2025.1713628"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1713628","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1713628"}}